Multicenter clinical research for investigating clinical utility of ESR1 and PIK3CA hotspot mutations detection and serial tracking using ultra-high sensitive method for metastatic hormone receptor positive breast cancer

Asan Medical Center0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年7月23日

试验速览

暂无简介。

•Age 19 or older at the time of obtaining consent
•- Patients diagnosed with hormone receptor positive, HER2 overexpression negative metastatic breast cancer
•- Patients using or planning to use CDK 4/6 inhibitor as conventional anti-hormonal treatment
•- Patients for whom primary breast cancer specimens were obtained at the time of diagnosis to confirm ESR1 and PIK3CA mutations
•- Patients with confirmed clinical pathology information such as age at the time of surgery, grade, tumor size, and presence of lymph node metastasis.
•- Patients eligible for imaging tests to evaluate treatment response
•- Patients eligible for serial blood sampling during anti-hormonal treatment

•- Patients diagnosed histologically with phyllodes tumor or sarcoma
•- Patients diagnosed with other cancers before breast cancer
•- Male breast cancer patient
•- Patients who have difficulty understanding research due to mental illness
•- Patients who plan to undergo follow-up at a location other than the research institution

发起方